Short term persistence of HPV 16 strongly predicted cervical intraepithelial neoplasia grade II+, with a three year cumulative incidence of 40.8% (26.4% to 55.1%).
Results Women who tested positive for a carcinogenic HPV at enrolment and after about one year (9-21 months) (positive/positive) had a three year cumulative incidence of cervical intraepithelial neoplasia grade II+ of 17.0%95%5% confidence interval 12.1% to 22.0%).
The five year cumulative primary patency rate by means of life table analysis was 37.8 ± 6.67% (SE).
Similar patterns were observed for the five year cumulative incidence of grade II+ and for three year and five year cumulative incidence of grade III+.
Five year cumulative survival was 30.7% in GSC, 41.2% in PGC, and 31.7% in EGJC.
Main outcome measures Primary end points: three year and five year cumulative incidence of histologically confirmed cervical intraepithelial neoplasia grade II+ (n=70).
Table 3 shows the three year and five year cumulative incidence of cervical intraepithelial neoplasia grade II+ and grade III+ after the 9-21 month follow-up visit.
The three year and five year cumulative incidence of cervical intraepithelial neoplasia grade II+ for women <30 was 19.0% (8.3% to 24.3%) and 20.3% (11.5% to 29.0%), respectively.
aBy comparison, five year cumulative probability of death from any cause in the Italian population for a group with the age and gender makeup of the calibration group has been estimated at 6.1% for 1990 [ 51].
The five year cumulative survival rate for patients stratified by NET morphologic subtypes was significantly higher in TC and AC [87.6% and 62.5%, respectively] than in the LCNECs and SCLC [24.2% and 20.7%, respectively].
Because the follow-up did not reach five years for most of the women, we analysed the five year cumulative hazard (that is, the cumulative detection rate) for precancerous and cancerous cervical lesions in both screening arms using the Nelson-Aalen estimator.
